Continuous Manufacturing Centers Of Excellence Measure Resurfaces In US House
Stand-alone bill headed for Senate, where it fared poorly in coronavirus response legislative packages.
You may also be interested in...
House tries again to promote advanced technology for the return of pharmaceutical manufacturing to the US in post-COVID-19 era.
The association for manufacturers of generics and biologics calls for public sector investment in priority medicines.
Under pressure to authorize use of Lilly’s bamlanivimab, the FDA must first weigh efficacy signals and GMP plant remediation progress.